Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers the following ways to purchase this medication. Choose the Best option for you!
Diflucan (fluconazole) is an antifungal medicine.
Diflucan is used to treat infections caused by fungus, which can invade any part of the body including the mouth, throat, esophagus, lungs, bladder, genital area, and the blood.
Diflucan is also used to prevent fungal infection in people who have a weak immune system caused by cancer treatment, bone marrow transplant, or diseases such as AIDS.
Diflucan is also used to treat a certain type of meningitis in people with HIV or AIDS.
Certain other drugs can cause unwanted or dangerous effects when used with Diflucan,especially cisapride, erythromycin, pimozide, quinidine, astemizole, higher doses of terfenadine, and many other medications that are broken down by certain enzymes Diflucan effects. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.
Before taking Diflucan, tell your doctor if you have liver disease, kidney disease, a heart rhythm disorder, or a history of Long QT syndrome.
Take Diflucan for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antifungal medication. Fluconazole will not treat a viral infection such as the common cold or flu.
You should not use Diflucan if you are allergic to fluconazole.
Some medicines can cause unwanted or dangerous effects when used with Diflucan. Your doctor may change your treatment plan if you also use:
an antibiotic, antifungal, or antiviral medicine;
a blood thinner;
cancer medicine;
cholesterol medication;
oral diabetes medicine;
heart or blood pressure medication;
medicine for malaria or tuberculosis;
medicine to prevent organ transplant rejection;
medicine to treat depression or mental illness;
an NSAID (nonsteroidal anti-inflammatory drug);
seizure medicine; or
steroid medicine.
Tell your doctor if you have ever had:
liver disease;
HIV or AIDS;
cancer;
heart disease or heart rhythm disorder;
long QT syndrome (in you or a family member);
kidney disease; or
if you are allergic to other antifungal medicine (such as ketoconazole, itraconazole, miconazole, posaconazole, voriconazole, and others).
The liquid form of Diflucan contains sucrose. Talk to your doctor before using this form of fluconazole if you have a problem digesting sugars or milk.
It is not known whether fluconazole will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It may not be safe to breastfeed while using Diflucan. Ask your doctor about any risk.
Take Diflucan exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
Your dose will depend on the infection you are treating. Vaginal infections are often treated with only one pill. For other infections, your first dose may be a double dose. Carefully follow your doctor's instructions.
You may take Diflucan with or without food.
Shake the oral suspension (liquid) before you measure a dose. Use the dosing syringe provided, or use a medicine dose-measuring device (not a kitchen spoon).
Use this medicine for the full prescribed length of time, even if your symptoms quickly improve. Skipping doses can increase your risk of infection that is resistant to medication. Fluconazole will not treat a viral infection such as the flu or a common cold.
Call your doctor if your symptoms do not improve, or if they get worse.
Store the tablets at room temperature away from moisture and heat.
You may store liquid Diflucan in a refrigerator, but do not allow it to freeze. Throw away any leftover liquid that is more than 2 weeks old.
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Overdose symptoms may include confusion or unusual thoughts or behavior.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.
Get emergency medical help if you have signs of an allergic reaction to Diflucan (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Call your doctor at once if you have:
fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);
fever, chills, body aches, flu symptoms;
easy bruising or bleeding, unusual weakness;
seizure (convulsions);
skin rash or skin lesions; or
liver problems - loss of appetite, stomach pain (upper right side), dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common Diflucan side effects may include:
nausea, stomach pain, diarrhea, upset stomach;
headache;
dizziness; or
changes in your sense of taste.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Fluconazole can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.
Many drugs can interact with fluconazole, and some drugs should not be used at the same time. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Tell your doctor about all your current medicines and any medicine you start or stop using.
Further informationRemember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Diflucan only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/27/2021.
Source: Drugs.com Diflucan (www.drugs.com/diflucan.html).
Note: This document contains side effect information about fluconazole. Some of the dosage forms listed on this page may not apply to the brand name Diflucan.
In SummaryMore frequent side effects include: vomiting. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to fluconazole: oral powder for suspension, oral tablet
Other dosage forms:
Along with its needed effects, fluconazole (the active ingredient contained in Diflucan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fluconazole:
Rare
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking fluconazole:
Symptoms of overdose
Some side effects of fluconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Incidence not known
For Healthcare Professionals
Applies to fluconazole: intravenous solution, oral powder for reconstitution, oral tablet
GeneralThis drug was generally well tolerated. Changes in renal and hematological function test results and hepatic abnormalities reported during therapy with this and comparative agents in some patients, primarily those with serious underlying diseases (e.g., AIDS, cancer); clinical significance and relationship to therapy unclear.
During clinical trials of single-dose therapy, side effects possibly related to therapy were reported in 26% of patients using this drug and 16% of patients using active comparative agents. The most common side effects reported in patients receiving a single 150 mg dose of this drug for vaginitis were headache, nausea, and abdominal pain. Most side effects were of mild to moderate severity.
During clinical trials of multiple-dose therapy, side effects were reported in 16% of patients. Therapy discontinuation occurred in 1.5% and 1.3% of patients due to adverse clinical events and laboratory test abnormalities, respectively. Clinical side effects were reported more often in HIV-infected patients than in non-HIV-infected patients (21% versus 13%), but the patterns in both groups were similar.
Nervous systemRare cases of seizures have been reported, but a causal relationship was difficult to establish, since some of these patients had cryptococcal meningitis or severe underlying disease. Nonetheless, at least 1 case of seizure following a 100 mg oral dose has been reported.
Seizures, dizziness, paresthesia, somnolence, tremor, and vertigo have also been reported during postmarketing experience.
Very common (10% or more): Headache (up to 13%)
Uncommon (0.1% to 1%): Seizures, dizziness, paresthesia, somnolence, vertigo, visual field defect, taste perversion, hyperkinesia, hypertonia
Rare (less than 0.1%): Tremor
Frequency not reported: Dysesthesias
GastrointestinalVery common (10% or more): Nausea, abdominal pain, diarrhea, vomiting
Common (1% to 10%): Dyspepsia
Uncommon (0.1% to 1%): Constipation, flatulence, loose stools, dry mouth
Frequency not reported: General abdominal discomfort
Dry mouth, dyspepsia, and vomiting have also been reported during postmarketing experience.
HepaticFatal hepatic reactions have occurred primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications. One reported patient with AIDS experienced acute hepatic necrosis and hepatic failure about 3 weeks after starting this drug.
Transient hepatic reactions have been reported in patients with no other identifiable risk factors. Liver function returned to baseline after stopping this drug.
Serum transaminase elevations (greater than 8 times the upper limit of normal [8 x ULN]; about 1%) and statistically significant increases in AST have been reported. Serum transaminase elevations have been reported primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications, including agents known to be hepatotoxic.
Transaminase elevations greater than 2 to 3 x ULN have also been reported.
Cholestasis, hepatocellular damage, and hepatocellular necrosis have also been reported during postmarketing experience.
Very common (10% or more): Increased ALT, increased AST
Uncommon (0.1% to 1%): Serum transaminase elevations, cholestasis, jaundice, increased bilirubin
Rare (less than 0.1%): Serious hepatic reactions, hepatic toxicity (including fatalities), hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage
Frequency not reported: Hepatic reactions (ranging from mild transient transaminase elevations to clinical hepatitis, fulminant hepatic failure [including fatalities]), transient hepatic reactions (including hepatitis, jaundice), elevated liver function tests (transient and asymptomatic), cholestatic jaundice, fatal hepatic necrosis, increased plasma levels of hepatic enzymes
DermatologicReversible alopecia has been associated with long-term (2 months or longer) therapy.
In patients with serious underlying diseases (primarily AIDS and malignancy), exfoliative skin disorders have resulted in a fatal outcome.
Acute generalized exanthematous pustulosis, drug eruption, increased sweating, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), and alopecia have also been reported during postmarketing experience.
Very common (10% or more): Rash
Common (1% to 10%): Maculopapular erythema
Uncommon (0.1% to 1%): Pruritus, genital pruritus, erythematous rash, dry skin, abnormal skin odor, urticaria, herpes simplex, drug eruption, increased sweating
Rare (less than 0.1%): Angioedema, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), alopecia, acute generalized exanthematous pustulosis, exfoliative dermatitis
Frequency not reported: Reversible alopecia, exfoliative skin disorders (including fatalities)
MetabolicVery common (10% or more): Increased blood alkaline phosphatase
Uncommon (0.1% to 1%): Hypokalemia, anorexia, decreased appetite
Rare (less than 0.1%): Hypercholesterolemia, hypertriglyceridemia
Hypercholesterolemia, hypertriglyceridemia, and hypokalemia have also been reported during postmarketing experience.
HypersensitivityRare cases of exfoliative dermatitis and ulcerative eruptions consistent with Stevens-Johnson syndrome have been reported in association with hypersensitivity reactions.
A 52-year-old female experienced a fixed drug eruption (FDE) when administered a single 400 mg oral dose for extensive pityriasis versicolor. Within 12 hours, she noticed 3 oval, painful, eroded, pigmented patches over her trunk with diameters of 3 to 4 cm and erythematous halos. A clinical diagnosis of FDE due to drug therapy was made. The FDE was confirmed when the patient was rechallenged with a 25 mg oral dose.
Rare (less than 0.1%): Anaphylactic reaction, anaphylaxis
Frequency not reported: Hypersensitivity reactions (including generalized edema, stridor, hypotension, exfoliative dermatitis, ulcerative eruptions), fixed drug eruption
Postmarketing reports: Anaphylaxis (including angioedema, face edema, pruritus)
CardiovascularMost reports of QT interval prolongation and torsades de pointes involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications that may have been contributory.
An 11-year-old male with neurofibromatosis-1 presented to the hospital in septic shock secondary to a perforated gastric volvulus. After initial stabilization, the patient underwent total gastrectomy and multiple peritoneal lavages. Culture of peritoneal fluid showed infection with Candida albicans. Therapy was started with fluconazole (the active ingredient contained in Diflucan) 150 mg IV every 12 hours. After starting this drug, the patient developed QT prolongation and complex ventricular arrhythmia. The drug was discontinued. Over the subsequent 36-hours, the patient remained in sinus rhythm except for one brief run of ventricular bigeminy. An ECG recorded 5 months after admission (and about 4 months after cessation of all QT-prolonging medications) showed sinus rhythm with normal heart rate and corrected QT interval.
QT prolongation and torsade de pointes have also been reported during postmarketing experience.
Rare (less than 0.1%): QT prolongation, torsade de pointes
Frequency not reported: Prolongation of the QT interval on the ECG, palpitations, complex ventricular arrhythmia
HematologicAnemia, eosinophilia, leukopenia, neutropenia, and thrombocytopenia have been reported, often in patients with severe deep fungal infections or underlying disease.
Spontaneous reports of anemia were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of anemia in the elderly. A causal relationship to drug exposure could not be determined.
Anemia, leukopenia, neutropenia, agranulocytosis, and thrombocytopenia have also been reported during postmarketing experience.
Uncommon (0.1% to 1%): Anemia
Rare (less than 0.1%): Leukopenia, neutropenia, agranulocytosis, thrombocytopenia
Frequency not reported: Eosinophilia
OtherUncommon (0.1% to 1%): Thirst, fatigue, malaise, pain, rigors, asthenia, fever, flushing, hot flushes
Rare (less than 0.1%): Face edema
Frequency not reported: Infection due to resistant microorganisms
Fever, asthenia, fatigue, and malaise have also been reported during postmarketing experience.
MusculoskeletalUncommon (0.1% to 1%): Back pain, myalgia
Frequency not reported: Joint pain, finger stiffness
Myalgia has also been reported during postmarketing experience.
PsychiatricUncommon (0.1% to 1%): Insomnia, nervousness
Insomnia has also been reported during postmarketing experience.
RenalUncommon (0.1% to 1%): Polyuria, renal pain, changes in renal function tests
Frequency not reported: Membranous nephropathy
Postmarketing reports: Acute renal failure
A 58-year-old female with a history of hypertension and cervical cancer experienced membranous nephropathy coincident with this drug. The patient presented with increasing generalized edema accompanied by nausea and indigestion for 3 weeks. Clinical findings showed the patient had stage I membranous nephropathy. At initial presentation, the patient's medication history included amlodipine, hydrochlorothiazide, metoclopramide, and levosulpiride. She did not admit to taking fluconazole. Five months after the initial presentation, the patient returned with reports of increasing pedal edema. At that point, the patient admitted to taking this drug once a week for tinea pedis. The patient went into complete remission when the drug was stopped.
Spontaneous reports of acute renal failure were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of renal failure in the elderly. A causal relationship to drug exposure could not be determined.
GenitourinaryUncommon (0.1% to 1%): Intermenstrual bleeding, dysmenorrhea, leukorrhea, menorrhagia, uterine spasm, vaginal disorders, female sexual dysfunction
RespiratoryUncommon (0.1% to 1%): Pharyngitis
Frequency not reported: Respiratory disorders
OcularUncommon (0.1% to 1%): Abnormal vision
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/27/2021.
Source: Drugs.com Diflucan (www.drugs.com/diflucan.html).
July 31, 2020
July 13, 2020
December 16, 2020
March 1, 2021
February 15, 2021
March 1, 2021